Roche (RHHBY) said the U.S. FDA has approved the company's Evrysdi (risdiplam) for the treatment of spinal muscular atrophy in adults and children 2 months of age and older. The company noted that Evrysdi is the first and only medicine for spinal muscular atrophy that can be taken at home. It will be available in the U.S. within two weeks for direct delivery to patients' homes through Accredo Health Group, an Express Scripts specialty pharmacy.
from RTT - Biotech https://ift.tt/3iqEGjT
via IFTTT
No comments:
Post a Comment